On Monday, Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. …

20 hours ago · Cantor Fitzgerald notes that the firm discovered “what appears” to be an “accidental release” of a snippet on the ASCO-GU daily news website highlighting data on …

22 hours ago · Cantor Fitzgerald reissued an "overweight" rating on shares of ORIC Pharmaceuticals in a research report on Tuesday, January 14th. Wells Fargo & Company …

1 day ago · On Monday, Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ: ORIC), currently trading at $13.39, after an incident involving a …

Feb 4, 2025 · On Tuesday, Cantor Fitzgerald reiterated its confidence in ORIC Pharmaceuticals (NASDAQ: ORIC), maintaining an Overweight stock rating. Trading at $11.49, ORIC has seen …

Jan 14, 2025 · Cantor Fitzgerald restated their overweight rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC - Free Report) in a research note issued to investors on …

Feb 23, 2024 · ORIC's lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to …

Feb 23, 2024 · On Friday, Cantor Fitzgerald initiated coverage on ORIC Pharmaceuticals (NASDAQ: ORIC), assigning an Overweight rating to the clinical-stage oncology-focused …

Jan 24, 2025 · ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for ORIC …

1 day ago · Na segunda-feira, a Cantor Fitzgerald reiterou sua classificação Overweight para a ORIC Pharmaceuticals (NASDAQ: ORIC), atualmente negociada a 13,39 USD, após um …